<DOC>
	<DOCNO>NCT00884858</DOCNO>
	<brief_summary>Suboptimal improvement cluster differentiation 4 ( CD4 ) cell count uncommon HIV-1-infected patient suppress plasma HIV-Ribonucleic acid ( RNA ) level , decrease CD4 cell count patient suppress low level viremia observe . Although efficacy current antiretroviral medication well establish , antiviral combination effective suppress HIV-1 load whereas exert effect immune reconstitution . Both T-cell immune activation fibrosis peripheral lymphoid tissue could create environment CD4 T cell count decrease set low suppress plasma viremia likely occur . Another fascinating hypothesis , still elucidate , reconstitution deplete CD4 pool block excess glycoprotein 120 ( gp120 ) HIV-1 protein . This extra-production could counteract inhibitor chemokine ( C-C motif ) receptor 5 ( CCR5 ) co-receptor represent one major dock tools HIV-1 . With mind , investigator would like propose design pilot exploratory clinical trial involve population HIV-1-infected patient rapidly reach virologic suppression without reconstitution immune system .</brief_summary>
	<brief_title>Maraviroc Immunological Non-Responder ( INR ) HIV-1-infected Subjects</brief_title>
	<detailed_description>Objectives : - Evaluate clinical efficacy HAART intensification MVC treatment HIV-1 infection patient CD4 count ≤ 200 cells/uL and/or recovery CD4 cell &lt; 25 % compare HAART initiation complete stable virologic suppression 12 month HAART . Patients could also include CD4 slope stable without improvement , absolute value around 200 cells/uL . - Evaluate effect HAART intensification MVC modification immunologic virologic parameter . - Evaluate tolerability HAART intensification MVC appearance drug-related side effect . Design : This randomise , multicenter , study evaluate HAART intensification MVC treatment HIV-1 infection patient CD4 count ≤ 200 cells/uL and/or recovery CD4 cell &lt; 25 % compare HAART initiation and/or stable CD4 slope without improvement , absolute value around 200 cells/uL complete stable virologic suppression 12 month HAART .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>age &gt; = 18 HIVAbs positivity detect ELISA confirm WesternBlot CD4 lymphocytes &lt; 200/uL and/or CD4 recovery &lt; 25 % least 12 month stable HAART HIVRNA &lt; 50 cp/mL last 12 month negative pregnancy test least 14 day prior treatment understand signing informed consent allergy/intolerance study drug less 1 year treatment immunomodulatory agent current OIs neoplasm current CVD EKG abnormalities current respiratory tract diseases COPD treatment steroid within 4 week treatment begin suspect autoimmune disorder chronic inflammatory disease active IVDUs alcohol addict AST ALT &gt; 2.5 ULD serum creatinine &gt; 1.5 ULD ANC &lt; 1000/uL hemoglobin &lt; 10 g/dL platelet &lt; 75.000/uL reticulocyte &gt; 2 % Karnofsky score &lt; 50</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>CD4</keyword>
	<keyword>INR</keyword>
	<keyword>HIV-1 infection</keyword>
	<keyword>extreme immunological compromission</keyword>
	<keyword>treatment experience</keyword>
</DOC>